P. Richardson

Molecular Biology · New England Journal of Medicine · 2000–2021

A researcher in the Science corpus: 40 papers; trusts 1 researcher and is trusted by 3 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 136 citations into it; #8,692 of 17,773 by trust here, #979 by citations

Whom P. Richardson trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. T. Hideshima

Who trusts P. Richardson overall

1. J. Adams
2. S. Rajkumar
3. T. Hideshima
4. F. Mantovani
5. S. Hatakeyama

Papers from P. Richardson's perspective

Ordered by how strongly the researchers P. Richardson trusts endorse each paper. Same corpus, a different order for every researcher.

1. A phase 2 study of bortezomib in relapsed, refractory myeloma. (New England Journal of Medicine)
2. International uniform response criteria for multiple myeloma (Leukemia)
3. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. (New England Journal of Medicine)
4. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma (British Journal of Haematology)
5. Molecular sequelae of proteasome inhibition in human multiple myeloma cells (Proceedings of the National Academy of Sciences of the United States of America)
6. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. (New England Journal of Medicine)
7. Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death (Science)
8. The proteasome: a suitable antineoplastic target (Nature Reviews. Cancer)
9. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. (New England Journal of Medicine)
10. Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis (Journal of Cell Biology)

Their papers

• BET bromodomain inhibition as a therapeutic strategy to target c-Myc (2011) — 2,801 citations
• Molecular sequelae of proteasome inhibition in human multiple myeloma cells (2002) — 787 citations
• Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets (2007) — 948 citations
• The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. (2003) — 747 citations
• Heterogeneity of genomic evolution and mutational profiles in multiple myeloma (2014) — 862 citations
• Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. (2005) — 610 citations
• A phase 2 study of bortezomib in relapsed, refractory myeloma. (2003) — 2,697 citations
• Proteasome inhibition as a novel therapeutic target in human cancer. (2005) — 597 citations
• NF-κB as a Therapeutic Target in Multiple Myeloma* (2002) — 869 citations
• Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. (2003) — 602 citations
• International uniform response criteria for multiple myeloma (2006) — 2,475 citations
• A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma (2004) — 758 citations
• Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. (2002) — 682 citations
• Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. (2000) — 921 citations
• International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (2014) — 4,253 citations
• A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. (2005) — 685 citations
• Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. (2002) — 819 citations
• CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002 (2021)
• Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. (2019) — 648 citations
• Lenalidomide, Bortezomib, and Dexamethasone with Transplantation in Myeloma. (2017) — 1,086 citations